Kuhre, Rune E.
Ghiasi, Seyed M.
Adriaenssens, Alice E.
Wewer Albrechtsen, Nicolai J.
Andersen, Daniel B.
Aivazidis, Alexander
Chen, Lihua
Mandrup-Poulsen, Thomas
Ørskov, Cathrine
Gribble, Fiona M.
Reimann, Frank
Wierup, Nils
Tyrberg, Björn
Holst, Jens J.
Funding for this research was provided by:
European Union’s Seventh Framework Programme for Research, Technological Development, and Demonstration Activities (Grant No. 266408)
Wellcome Trust (106262/Z/14/Z and 106263/Z/14/Z)
Novo Nordisk Foundation (NNF15OC0016574)
European Research Council (Grant no.695069)
Novo Nordisk Center for Basic Metabolic Research (Personal unrestricted grant to Prof. Jens J Holst)
Lundbeckfonden (R264-2017-3492)
Article History
Received: 17 November 2018
Accepted: 12 February 2019
First Online: 22 March 2019
Duality of interest
: AA, LC and BT are employed by AstraZeneca. AstraZeneca had no involvement in the conception of study, design and execution of experiments, interpretation of data or writing of the manuscript. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
Free to read: This content has been made available to all.